Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 59 clinical trials
The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients.

decrease of arterial stiffness. Preclinical work has shown that the vascular toxicity of cyclosporine is mediated by activation of the mineralocorticoid receptor in smooth muscle cells. The

  • 0 views
  • 04 Oct, 2022
  • 1 location
Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function

liver function or HAAA patients treated for the first time. The design was: Patients received p-ATG for 5 consecutive days (day 1-5), at a dose of 20 mg/kg/day. Cyclosporine 3 mg/kg orally in two

  • 0 views
  • 29 Oct, 2022
  • 1 location
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)

The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with

remission
filgrastim
granulocyte colony stimulating factor
cytopenia
ejection fraction
  • 76 views
  • 21 Apr, 2022
  • 2 locations
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

) following the transplant. Two drugs, cyclosporine (CSP) and sirolimus (SIR), will be combined with either mycophenolate mofetil (MMF) or post-transplant cyclophosphamide (PTCy). This part of the transplant

chronic myelomonocytic leukemia
lymphocytic leukemia
idelalisib
chronic myeloid leukemia
multiple myeloma
  • 64 views
  • 05 Jun, 2022
  • 1 location
NATIENS: Optimal Management and Mechanisms of SJS/TEN (NATIENS)

The NATIENS study is a phase III randomized study to examine the optimal treatment and mechanisms of each of two treatments (cyclosporine 5 mg/kg bid for 14 days versus etanercept 50 mg

  • 0 views
  • 10 Apr, 2023
  • 1 location
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after

lymphocytic leukemia
total body irradiation
chronic myeloid leukemia
left ventricular fractional shortening
carbon monoxide
  • 129 views
  • 07 Oct, 2022
  • 1 location
CLAG·M Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study

transplanted cells from a donor can attack the body's normal cells called graft versus host disease. Giving cyclophosphamide, cyclosporine, and mycophenolate mofetil after the transplant may stop this from

  • 0 views
  • 13 Oct, 2022
  • 1 location
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

bone marrow to stop making red blood cells, platelets, and white blood cells. Standard treatment for this disease is horse-ATG and cyclosporine, which suppress the immune system and stop it from

blood test
immunosuppression
platelet count
anemia
immunosuppressant
  • 115 views
  • 06 Apr, 2023
  • 1 location
GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide

mortality after HSCT, and prophylactic strategies are routinely used. In the context of haploidentical HCT, posttransplant cyclophosphamide plus cyclosporine and mycophenolate mofetil (MMF) is the most

remission
ejection fraction
chronic myeloid leukemia
cell transplantation
mycophenolate mofetil
  • 0 views
  • 23 Sep, 2021
  • 4 locations
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

cell and white blood cell transplant, participants will have regular doses of cyclosporine and methotrexate to prevent rejection of the donor cells. Participants will have three doses of methotrexate

filgrastim
granulocyte colony stimulating factor
hterc
neutropenia
pancytopenia
  • 52 views
  • 06 Apr, 2023
  • 3 locations